一种小分子PTER选择性抑制剂减少了食物摄入量和体重
Sipei Fu1, Lushun Wang2, Veronica L Li3
1Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA; Sarafan ChEM-H, Stanford University, Stanford, CA, USA; Department of Biology, Stanford University, Stanford, CA, USA.
Cell chemical biology
|March 10, 2026
概括
研究人员开发了一种用于三酶相关 (PTER) 酶的新型抑制剂. 这种PTER抑制剂在减少肥胖小鼠的食和帮助减肥方面表现有前途,为肥胖小鼠提供了一个新的治疗途径.
科学领域:
- 生物化学 生物化学
- 代谢性疾病研究研究.
- 结构生物学是结构生物学.
背景情况:
- 与三酶相关的 (PTER) 酶催化N-乙氨酸,一种厌食性代谢物.
- 对于PTER的连接体结合和催化机制的结构基础尚不清楚.
- 了解PTER对于对代谢途径的治疗向至关重要.
研究的目的:
- 阐明 PTER 带结合和催化作用的结构基础.
- 为了设计一种强效和选择性的PTER抑制剂.
- 在肥胖模型中评估PTER抑制的治疗潜力.
主要方法:
- 在阿波和产品结合状态下确定真核细胞PTER的晶体结构.
- 确定了PTER和基因素脱乙酶 (HDAC) 酶之间的结构同质性.
- 设计了一个基质竞争性PTER抑制剂 (PTERi),并在体外测试了其对PTER和HDAC的选择性和功效.
- 向饮食诱导的肥胖小鼠施用PTERi,以评估其对养行为和体重减轻的影响.
主要成果:
- 晶体结构揭示了PTER和HDAC之间的意想不到的口袋同质性.
- 开发出具有纳米分子强度和高选择性 (>100倍) 的PTERi比HDACs.
- 在肥胖小鼠中,PTERi的使用减少了由GLP1-RA引起的食和增强体重减轻.
- 在停止GLP1-RA治疗后,PTERi可以防止体重恢复.
结论:
- PTER结构提供了一个连接基因组和代谢物脱乙化的框架.
- 药理上抑制PTER是一种可行的肥胖治疗策略.
- PTERi证明了针对PTER的肥胖药物疗法的概念证明.
关键词:
在HDAC的基础上,HDAC是乙酸乙烯的使用方法身体质量指数 (BMI) 是指身体质量指数.酵素酶是一种酶.抑制剂抑制剂的作用肥胖 肥胖 肥胖 肥胖 肥胖 肥胖 肥胖 肥胖taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine taurine 是一种类型的氨基酸
相关概念视频
01:30Regulation of Food Intake
3.0K
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
3.0K
01:24Glucagon-like Receptor Agonists
1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K